Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Seed VC | Alive

About Avillion

Avillion focuses on clinical co-development of therapeutics. The company is partnering with pharmaceutical and biotechnology companies to co-develop and finance latestage therapeutics. The company will use its clinical development and regulatory expertise to obtain global approvalsfor a broad range of drugs and biologics.

Avillion Headquarters Location

London, England,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Avillion News

Avillion Chooses BSI's eClinical Software for its Clinical Operation

Sep 8, 2022

Avillion Chooses BSI's eClinical Software for its Clinical Operation Ansprechpartner:in Frau Charlotte Malz +41 41 766 86 33 ) BSI announces that it has been awarded the contract for the supply of its Clinical Trial Management System (CTMS) to Avillion LLP. Avillion is a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval. Avillion selected the BSI CTMS as they felt it met their objectives of being a modular solution across a broad range of functions required to manage and oversee large and complex trial programs. In addition, the platform provides a flexible solution with a high level of configuration without the need for programming, facilitating optimal support of business needs in the evolving clinical research environment. BSI CTMS also comes with fully integrated eTMF and LMS modules, avoiding the need for clients to purchase and integrate other solutions. The Avillion Operations Director said “Being a small company, it was essential for us to be able to find a system that was flexible and met our needs, but was also quick and simple to implement and maintain in-house. Having worked closely with BSI to implement the system, we are delighted with the ease at which we have been able to incorporate the BSI CTMS system into our working practices”. Jan Nielsen, Community Manager, Life Sciences at BSI, commented: “Avillion was not only looking for an eClinical tool, but a software provider that would partner with them to invest in understanding their processes and adapting to specific operational needs. Our Clinical Trial Management System stands out for its great flexibility, something our clients love and value. The collaboration with Avillion proves that BSI can successfully deliver not only to companies working with traditional business models, but also to innovative players bringing change to their industries.” About Avillion Avillion offers pharma partners an innovative model providing additional funding and clinical development expertise, to maximise the potential of new and existing assets. Avillion takes on the full clinical and regulatory risk, focusing on the speed and quality of trial execution. Typically supporting programs post proof-of-concept through to registration and with an agnostic approach to therapy area, Avillion prides itself in adding value around operational expertise while being backed by established life science investors. For more information, please visit: About BSI Life Sciences BSI offers smart eClinical software for CTMS, eTMF and more. BSI makes life science software for people – and has done so for 25+ years. BSI’s software solutions made in Switzerland, Germany, USA, and anywhere else clients need them to be, are innovative and user-friendly. They focus resources on staying ahead of the trends and delivering functional, compliant, and affordable eClinical software. In this way, BSI helps its customers continuously optimize and accelerate the clinical development process. And that’s what they love! For more information, please visit:

  • Where is Avillion's headquarters?

    Avillion's headquarters is located at London.

  • What is Avillion's latest funding round?

    Avillion's latest funding round is Seed VC.

  • Who are the investors of Avillion?

    Investors of Avillion include Clarus and Abingworth.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.